Batten Disease Treatment Market, 2012 to 2023
Batten disease treatment market: Batten disease is most common group of disorders called Neuronal Ceroid Lipofuscinoses (NCLs). Batten disease is a rare, fatal and inherited nervous system disorder that generally begins in childhood. It is also caused by lysosome shortage. The symptoms in initial stages will be vision loss in previously healthy children followed by slow learning, personality and behavioural changes. Commonly within 2-4 years of vision loss seizures may appear. Generally, neuronal ceroid lipofuscinoses are classified into infantile NCL (INCL), late infant NCL (LINCL), juvenile NCL (JNCL) and adult NCL.
Market Outline: Global Batten disease Treatment
Batten disease treatment market is driven by an increase in R&D activities for development of new treatments for batten disease. In addition, lack of effective treatment options and increase in prevalence rates of batten disease treatment market are expected to boost the market growth over the forecast period. Furthermore, recent drug launches and growing awareness related to symptoms of disease are anticipated to bolster the batten disease treatment market during the forecast period. However, high cost of drug development, unavailability of many treatments for batten disease and a low number of patients are expected to hamper the market growth over the forecast period.
Global Batten disease Treatment market is segmented based on type of disease, treatment and distribution channel
Based on type of disease, batten disease treatment is segmented into
Juvenile NCL (JNCL)
Infantile NCL (INCL)
Late infant NCL (LINCL)
Adult NCL
Others
Based on treatment, batten disease treatment market is segmented into
Gene Therapy
Drug Therapy
Enzyme Therapy
Others
Based on distribution channel, batten disease treatment market is segmented into
Hospital Pharmacies
Retail Pharmacies
Others
According to National Institute of Neurological Disorders and Stroke, Batten disease occurs in an estimated 2 to 4 of every 100,000 live birth in U.S., and it is more common in Sweden, Finland, other parts of Northern Europe, and Newfoundland, Canada. Batten disease treatment market is still in development stage. Companies are adopting licencing and collaborations to increase market share. For instance, In June 2015, Abeona Therapeutics, Inc. (formerly PlasmaTech Biopharmaceuticals, Inc.) got worldwide exclusive rights to an AAV gene therapy for treatment of juvenile batten disease fromUNeMed Corporation, a technology transfer company. In addition, many of the research and educational institutions focused on the development of new treatments for batten disease. Furthermore, government and non-government organizations such as Batten Disease Support and Research Association, Beyond The Batten Disease Foundation and others are actively participating in increasing the awareness about the batten disease and further expected to boost the growth of market.
Geographically, batten disease treatment market has been segmented into Latin America, Europe, Asia-Pacific, North America, and the Middle East & Africa. North America and Europe batten disease treatment market growth is attributed to increasing in R&D expenditure, growing awareness related to the batten disease due to various awareness programs being taken by the non-government and government organizations in the region. Furthermore, well-established infrastructure and recent drug launches are expected to boost the market in the U.S. region. Asia Pacific region market is expected to offer lucrative growth due to lower R&D costs, developing healthcare infrastructure and growing prevalence rates of genetic disorders.
Some of the players in batten disease treatment market are Abeona Therapeutics Inc. (U.S.), BioMarin Pharmaceutical Inc. (U.S.), CereSpir Inc. (U.S.), Evotec AG (Germany), Ionis Pharmaceuticals Inc. (U.S.), Mitochon Pharmaceuticals Inc. (U.S.), and Spark Therapeutics Inc. (U.S.) to name a few.
In April 2017, U.S. FDA has approved BioMarin Pharmaceutical Inc.’s Brineura, the first FDA approved treatment for a form of batten disease
Market Outline: Global Batten disease Treatment
Batten disease treatment market is driven by an increase in R&D activities for development of new treatments for batten disease. In addition, lack of effective treatment options and increase in prevalence rates of batten disease treatment market are expected to boost the market growth over the forecast period. Furthermore, recent drug launches and growing awareness related to symptoms of disease are anticipated to bolster the batten disease treatment market during the forecast period. However, high cost of drug development, unavailability of many treatments for batten disease and a low number of patients are expected to hamper the market growth over the forecast period.
Global Batten disease Treatment market is segmented based on type of disease, treatment and distribution channel
Based on type of disease, batten disease treatment is segmented into
Juvenile NCL (JNCL)
Infantile NCL (INCL)
Late infant NCL (LINCL)
Adult NCL
Others
Based on treatment, batten disease treatment market is segmented into
Gene Therapy
Drug Therapy
Enzyme Therapy
Others
Based on distribution channel, batten disease treatment market is segmented into
Hospital Pharmacies
Retail Pharmacies
Others
According to National Institute of Neurological Disorders and Stroke, Batten disease occurs in an estimated 2 to 4 of every 100,000 live birth in U.S., and it is more common in Sweden, Finland, other parts of Northern Europe, and Newfoundland, Canada. Batten disease treatment market is still in development stage. Companies are adopting licencing and collaborations to increase market share. For instance, In June 2015, Abeona Therapeutics, Inc. (formerly PlasmaTech Biopharmaceuticals, Inc.) got worldwide exclusive rights to an AAV gene therapy for treatment of juvenile batten disease fromUNeMed Corporation, a technology transfer company. In addition, many of the research and educational institutions focused on the development of new treatments for batten disease. Furthermore, government and non-government organizations such as Batten Disease Support and Research Association, Beyond The Batten Disease Foundation and others are actively participating in increasing the awareness about the batten disease and further expected to boost the growth of market.
Geographically, batten disease treatment market has been segmented into Latin America, Europe, Asia-Pacific, North America, and the Middle East & Africa. North America and Europe batten disease treatment market growth is attributed to increasing in R&D expenditure, growing awareness related to the batten disease due to various awareness programs being taken by the non-government and government organizations in the region. Furthermore, well-established infrastructure and recent drug launches are expected to boost the market in the U.S. region. Asia Pacific region market is expected to offer lucrative growth due to lower R&D costs, developing healthcare infrastructure and growing prevalence rates of genetic disorders.
Some of the players in batten disease treatment market are Abeona Therapeutics Inc. (U.S.), BioMarin Pharmaceutical Inc. (U.S.), CereSpir Inc. (U.S.), Evotec AG (Germany), Ionis Pharmaceuticals Inc. (U.S.), Mitochon Pharmaceuticals Inc. (U.S.), and Spark Therapeutics Inc. (U.S.) to name a few.
In April 2017, U.S. FDA has approved BioMarin Pharmaceutical Inc.’s Brineura, the first FDA approved treatment for a form of batten disease
1. EXECUTIVE SUMMARY
2. GLOBAL BATTEN DISEASE TREATMENT MARKET INTRODUCTION
2.1. Global Batten Disease Treatment Market – Taxonomy
2.2. Global Batten Disease Treatment Market –Definitions
2.2.1. Disease Type
2.2.2. Distribution Channel
3. GLOBAL BATTEN DISEASE TREATMENT MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Batten Disease Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Batten Disease Treatment Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Batten Disease Treatment Market – Product Innovations
4. GLOBAL BATTEN DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL BATTEN DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Disease Type Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
5.1.1. Juvenile NCL (JNCL)
5.1.2. Infantile NCL (INCL)
5.1.3. Late infant NCL (LINCL)
5.1.4. Adult NCL
5.1.5. Others
5.1.6. Market Opportunity Analysis
6. GLOBAL BATTEN DISEASE TREATMENT MARKET FORECAST, BY TREATMENT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Gene Therapy
6.2. Drug Therapy
6.3. Enzyme Therapy
6.4. Others
6.5. Market Opportunity Analysis
7. GLOBAL BATTEN DISEASE TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
8. GLOBAL BATTEN DISEASE TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
8.6. Global Batten Disease Treatment Market - Opportunity Analysis Index, By Disease Type, Diseases Type, Distribution Channel, and Region, 2017 – 2023
9. NORTH AMERICA BATTEN DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Juvenile NCL (JNCL)
9.1.1.2. Infantile NCL (INCL)
9.1.1.3. Late infant NCL (LINCL)
9.1.1.4. Adult NCL
9.1.1.5. Others
9.1.1.6. Market Opportunity Analysis
9.1.2. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. Gene Therapy
9.1.2.2. Drug Therapy
9.1.2.3. Enzyme Therapy
9.1.2.4. Others
9.1.2.5. Market Opportunity Analysis
9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Hospital Pharmacies
9.1.3.2. Retail Pharmacies
9.1.3.3. Others
9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Batten Disease Treatment Market - Opportunity Analysis Index, By Disease Type, Disease Type, Distribution Channel and Country, 2017 – 2023
9.1.6. North America Batten Disease Treatment Market Dynamics – Trends
10. EUROPE BATTEN DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Juvenile NCL (JNCL)
10.1.1.2. Infantile NCL (INCL)
10.1.1.3. Late infant NCL (LINCL)
10.1.1.4. Adult NCL
10.1.1.5. Others
10.1.1.6. Market Opportunity Analysis
10.1.2. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Gene Therapy
10.1.2.2. Drug Therapy
10.1.2.3. Enzyme Therapy
10.1.2.4. Others
10.1.2.5. Market Opportunity Analysis
10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Hospital Pharmacies
10.1.3.2. Retail Pharmacies
10.1.3.3. Others
10.1.3.4. Market Opportunity Analysis
10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Batten Disease Treatment Market - Opportunity Analysis Index, By Disease Type, Distribution Channel, and Country, 2017 – 2023
10.1.6. Europe Batten Disease Treatment Market Dynamics – Trends
11. ASIA-PACIFIC BATTEN DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Juvenile NCL (JNCL)
11.1.1.2. Infantile NCL (INCL)
11.1.1.3. Late infant NCL (LINCL)
11.1.1.4. Adult NCL
11.1.1.5. Others
11.1.1.6. Market Opportunity Analysis
11.1.2. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Gene Therapy
11.1.2.2. Drug Therapy
11.1.2.3. Enzyme Therapy
11.1.2.4. Others
11.1.2.5. Market Opportunity Analysis
11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Hospital Pharmacies
11.1.3.2. Retail Pharmacies
11.1.3.3. Others
11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Japan
11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Batten Disease Treatment Market - Opportunity Analysis Index, By Disease Type, Distribution Channel, and Country, 2017 – 2023
11.1.6. Europe Batten Disease Treatment Market Dynamics – Trends
12. LATIN AMERICA BATTEN DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Juvenile NCL (JNCL)
12.1.1.2. Infantile NCL (INCL)
12.1.1.3. Late infant NCL (LINCL)
12.1.1.4. Adult NCL
12.1.1.5. Others
12.1.1.6. Market Opportunity Analysis
12.1.2. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Gene Therapy
12.1.2.2. Drug Therapy
12.1.2.3. Enzyme Therapy
12.1.2.4. Others
12.1.2.5. Market Opportunity Analysis
12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Hospital Pharmacies
12.1.3.2. Retail Pharmacies
12.1.3.3. Others
12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Batten Disease Treatment Market - Opportunity Analysis Index, By Disease Type, Distribution Channel, and Country, 2017 – 2023
12.1.6. Latin America Batten Disease Treatment Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA BATTEN DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1.1. Juvenile NCL (JNCL)
13.1.1.2. Infantile NCL (INCL)
13.1.1.3. Late infant NCL (LINCL)
13.1.1.4. Adult NCL
13.1.1.5. Others
13.1.1.6. Market Opportunity Analysis
13.1.2. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. Gene Therapy
13.1.2.2. Drug Therapy
13.1.2.3. Enzyme Therapy
13.1.2.4. Others
13.1.2.5. Market Opportunity Analysis
13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Hospital Pharmacies
13.1.3.2. Retail Pharmacies
13.1.3.3. Others
13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Gulf Cooperation Council (GCC) Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Batten Disease Treatment Market - Opportunity Analysis Index, By Disease Type, Distribution Channel, and Country, 2017 – 2023
13.1.6. MEA Batten Disease Treatment Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Abeona Therapeutics Inc. (U.S.)
14.2.2. BioMarin Pharmaceutical Inc. (U.S.)
14.2.3. CereSpir Inc. (U.S.)
14.2.4. Evotec AG (Germany)
14.2.5. Ionis Pharmaceuticals Inc. (U.S.)
14.2.6. Mitochon Pharmaceuticals Inc. (U.S.)
14.2.7. Spark Therapeutics Inc. (U.S.)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL BATTEN DISEASE TREATMENT MARKET INTRODUCTION
2.1. Global Batten Disease Treatment Market – Taxonomy
2.2. Global Batten Disease Treatment Market –Definitions
2.2.1. Disease Type
2.2.2. Distribution Channel
3. GLOBAL BATTEN DISEASE TREATMENT MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Batten Disease Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Batten Disease Treatment Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Batten Disease Treatment Market – Product Innovations
4. GLOBAL BATTEN DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL BATTEN DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Disease Type Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
5.1.1. Juvenile NCL (JNCL)
5.1.2. Infantile NCL (INCL)
5.1.3. Late infant NCL (LINCL)
5.1.4. Adult NCL
5.1.5. Others
5.1.6. Market Opportunity Analysis
6. GLOBAL BATTEN DISEASE TREATMENT MARKET FORECAST, BY TREATMENT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Gene Therapy
6.2. Drug Therapy
6.3. Enzyme Therapy
6.4. Others
6.5. Market Opportunity Analysis
7. GLOBAL BATTEN DISEASE TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
8. GLOBAL BATTEN DISEASE TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
8.6. Global Batten Disease Treatment Market - Opportunity Analysis Index, By Disease Type, Diseases Type, Distribution Channel, and Region, 2017 – 2023
9. NORTH AMERICA BATTEN DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Juvenile NCL (JNCL)
9.1.1.2. Infantile NCL (INCL)
9.1.1.3. Late infant NCL (LINCL)
9.1.1.4. Adult NCL
9.1.1.5. Others
9.1.1.6. Market Opportunity Analysis
9.1.2. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. Gene Therapy
9.1.2.2. Drug Therapy
9.1.2.3. Enzyme Therapy
9.1.2.4. Others
9.1.2.5. Market Opportunity Analysis
9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Hospital Pharmacies
9.1.3.2. Retail Pharmacies
9.1.3.3. Others
9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Batten Disease Treatment Market - Opportunity Analysis Index, By Disease Type, Disease Type, Distribution Channel and Country, 2017 – 2023
9.1.6. North America Batten Disease Treatment Market Dynamics – Trends
10. EUROPE BATTEN DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Juvenile NCL (JNCL)
10.1.1.2. Infantile NCL (INCL)
10.1.1.3. Late infant NCL (LINCL)
10.1.1.4. Adult NCL
10.1.1.5. Others
10.1.1.6. Market Opportunity Analysis
10.1.2. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Gene Therapy
10.1.2.2. Drug Therapy
10.1.2.3. Enzyme Therapy
10.1.2.4. Others
10.1.2.5. Market Opportunity Analysis
10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Hospital Pharmacies
10.1.3.2. Retail Pharmacies
10.1.3.3. Others
10.1.3.4. Market Opportunity Analysis
10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Batten Disease Treatment Market - Opportunity Analysis Index, By Disease Type, Distribution Channel, and Country, 2017 – 2023
10.1.6. Europe Batten Disease Treatment Market Dynamics – Trends
11. ASIA-PACIFIC BATTEN DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Juvenile NCL (JNCL)
11.1.1.2. Infantile NCL (INCL)
11.1.1.3. Late infant NCL (LINCL)
11.1.1.4. Adult NCL
11.1.1.5. Others
11.1.1.6. Market Opportunity Analysis
11.1.2. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Gene Therapy
11.1.2.2. Drug Therapy
11.1.2.3. Enzyme Therapy
11.1.2.4. Others
11.1.2.5. Market Opportunity Analysis
11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Hospital Pharmacies
11.1.3.2. Retail Pharmacies
11.1.3.3. Others
11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Japan
11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Batten Disease Treatment Market - Opportunity Analysis Index, By Disease Type, Distribution Channel, and Country, 2017 – 2023
11.1.6. Europe Batten Disease Treatment Market Dynamics – Trends
12. LATIN AMERICA BATTEN DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Juvenile NCL (JNCL)
12.1.1.2. Infantile NCL (INCL)
12.1.1.3. Late infant NCL (LINCL)
12.1.1.4. Adult NCL
12.1.1.5. Others
12.1.1.6. Market Opportunity Analysis
12.1.2. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Gene Therapy
12.1.2.2. Drug Therapy
12.1.2.3. Enzyme Therapy
12.1.2.4. Others
12.1.2.5. Market Opportunity Analysis
12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Hospital Pharmacies
12.1.3.2. Retail Pharmacies
12.1.3.3. Others
12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Batten Disease Treatment Market - Opportunity Analysis Index, By Disease Type, Distribution Channel, and Country, 2017 – 2023
12.1.6. Latin America Batten Disease Treatment Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA BATTEN DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1.1. Juvenile NCL (JNCL)
13.1.1.2. Infantile NCL (INCL)
13.1.1.3. Late infant NCL (LINCL)
13.1.1.4. Adult NCL
13.1.1.5. Others
13.1.1.6. Market Opportunity Analysis
13.1.2. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. Gene Therapy
13.1.2.2. Drug Therapy
13.1.2.3. Enzyme Therapy
13.1.2.4. Others
13.1.2.5. Market Opportunity Analysis
13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Hospital Pharmacies
13.1.3.2. Retail Pharmacies
13.1.3.3. Others
13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Gulf Cooperation Council (GCC) Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Batten Disease Treatment Market - Opportunity Analysis Index, By Disease Type, Distribution Channel, and Country, 2017 – 2023
13.1.6. MEA Batten Disease Treatment Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Abeona Therapeutics Inc. (U.S.)
14.2.2. BioMarin Pharmaceutical Inc. (U.S.)
14.2.3. CereSpir Inc. (U.S.)
14.2.4. Evotec AG (Germany)
14.2.5. Ionis Pharmaceuticals Inc. (U.S.)
14.2.6. Mitochon Pharmaceuticals Inc. (U.S.)
14.2.7. Spark Therapeutics Inc. (U.S.)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
